Abstract     Description     Claims     Drawing  

US61935748   [0001] 
WO2006129163A   [0048] 
US20060153808A   [0048] 
US13075932W   [0058] 
US4816567A   [0064] 
US7488802B   [0068] 
US7521051B   [0068] 
US8008449B   [0068] 
US8354509B   [0068] 
US8168757B   [0068] 
WO2004004771A   [0068] 
WO2004072286A   [0068] 
WO2004056875A   [0068] 
US20110271358A   [0068] 
WO2008156712A   [0068]  [0075]  [0075]  [0075]  [0075] 
WO2013019906A   [0069]  [0069]  [0147] 
WO201O077634A1   [0069] 
US8383796B   [0069] 
WO2010027827A   [0070] 
WO2011066342A   [0070] 
US8337850B   [0099]  [0143] 
US20130078240A   [0099] 
WO2012135408A   [0142] 
US6329511B   [0150] 

Sequences of Proteins of Immunological Interest   [0038]  [0039] 
Adv. Prot. Chem.   [0038] 
J. Biol. Chem.   [0038] 
J Mol. Biol.   [0038] 
Nature   [0038] 
J. Mol. Biol.   [0039] 
Annals of Applied Biology   [0051] 
JMB   [0053] 
Molecular Biology of the Gene   [0054] 
Clin Cancer Res   [0058] 
J. Mol. Biol.   [0061] 
Nature Genet   [0061] 
Meth. Enzymol.   [0061] 
Nucleic Acids Res.   [0061] 
Genome Res.   [0061] 
Comput. Chem.   [0061] 
Comput. Appl. Biosci.   [0061] 
A model of evolutionary change in proteins   [0061] 
Matrices for detecting distant relationships   [0061] 
J. Mol. Biol.   [0061] 
Methods   [0061] 
Proc. Natl. Acad. Sci. USA   [0061] 
J. Mol. Evol.   [0061] 
Proc. Natl. Acad. Sci. USA   [0061] 
Proc. Natl. Acad. Sci. USA   [0061] 
Ann. Prob.   [0061] 
Evaluating the statistical significance of multiple distinct local alignments   [0061] 
Sequences of Proteins of Immunological Interest   [0063] 
Nature   [0064] 
Nature   [0064] 
J. Mol. Biol.   [0064] 
J. Allergy Clin. Immunol.   [0064] 
WHO Drug Information   [0068] 
WHO Drug Information   [0068] 
PNAS   [0078] 
Cancer Res.   [0078] 
Cancer   [0078] 
Sci Transl Med   [0078] 
New Eng. J Med.   [0078] 
Eur. J Cancer   [0083] 
J. Nucl. Med.   [0087] 
Cancer Gene Therapy   [0093] 
Agnew, Chem. Intl. Ed. Engl.   [0109] 
Antibody Therapy   [0122] 
Monoclonal Antibodies, Cytokines and Arthritis   [0122] 
Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases   [0122] 
New Engl. J. Med.   [0122] 
New Engl. J. Med.   [0122] 
New Engl. J. Med.   [0122] 
New Engl. J. Med.   [0122] 
New Engl. J. Med.   [0122] 
New Engl. J. Med.   [0122] 
Physicians' Desk Reference 2003 (Physicians' Desk Reference, 57th Ed)   [0122] 
New Engl. J. Med.   [0123] 
New Engl. J. Med.   [0123] 
J. Neurol. Neurosurg. Psych.   [0123] 
Cancer Immunol. Immunother.   [0123] 
Molecular Cloning, A Laboratory Manual   [0148] 
Molecular Cloning   [0148] 
Recombinant DNA   [0148] 
Current Protocols in Molecular Biology   [0148] 
DNA mutagenesis   [0148] 
mammalian cells and yeast   [0148] 
protein expression   [0148] 
bioinformatics   [0148] 
Current Protocols in Protein Science   [0149] 
Current Protocols in Protein Science   [0149] 
Current Protocols in Molecular Biology   [0149] 
Products for Life Science Research   [0149] 
Amersham Pharmacia Biotech   [0149] 
Current Protcols in Immunology   [0149] 
Using Antibodies   [0149] 
Current Protocols in Immunology   [0149] 
Monoclonal Antibodies   [0150] 
Antibody Engineering   [0150] 
Antibodies A Laboratory Manual   [0150] 
J. Immunol.   [0150] 
J. Immunol.   [0150] 
J. Biol. Chem.   [0150] 
J. Biol. Chem.   [0150] 
Nature   [0150] 
J. Mol. Biol.   [0150] 
Nature Biotechnol.   [0151] 
Nature Medicine   [0151] 
Nature Genetics   [0151] 
Immunol. Today   [0151] 
Phage Display: A Laboratory Manual   [0151] 
Phage Display of Peptides and Proteins: A Laboratory Manual   [0151] 
Nature Biotechnol.   [0151] 
Immunity   [0152] 
Immunity   [0152] 
J. Immunol.   [0152] 
J. Immunol.   [0153] 
J. Immunol.   [0153] 
J. Immunol.   [0153] 
J. Immunol.   [0153] 
Flow Cytometry Principles for Clinical Laboratory Practice   [0154] 
Flow Cytometry   [0154] 
Practical Flow Cytometry   [0154] 
Molecular Probesy   [0154] 
Human Thymus: Histopathology and Pathology   [0155] 
Color Atlas of Histology   [0155] 
Basic Histology: Text and Atlas   [0155] 
Bioinformatics   [0156] 
Bioinformatics Applications Note   [0156] 
Comput. Methods Programs Biomed.   [0156] 
Eur. J. Biochem.   [0156] 
Nucleic Acids Res.   [0156] 
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection   [0165] 
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion   [0165] 
PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro   [0165] 
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk propgnostic factors   [0165] 
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer   [0165] 
Significance of B7-H1 overexpression in kidney cancer. Clinical genitourin   [0165] 
Clinical significance and therapeutic potential of the programmed death- 1 ligand/programmed death-1 pathway in human pancreatic cancer   [0165] 
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand 2 expression in human esophageal cancer   [0165] 
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression   [0165] 
Augmented expression of programmed death-1 in both neoplasmatic and nonneoplastic CD4+ T-cells in adult T-cell Leukemia/ Lymphoma   [0165] 
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma   [0165] 
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers   [0165] 
Tumor cell expression of programmed cell death-1 is a prognostic factor for malignant melanoma   [0165] 
Foxp3+ tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy   [0165] 
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired   [0165] 
PD-1 is expressed by tumor infiltrating cells and is associated with poor outcome for patients with renal carcinoma   [0165] 
Immune regulation by 4-1BB and 4-1BBL: complexities and challenges   [0165] 
CD137 promotes proliferation and survival of human B cells   [0165] 
CD137 expression in tumor vessel walls. High correlation with malignant tumors   [0165] 
Genes that distinguish physiological and pathological angiogenesis   [0165] 
CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice   [0165] 
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion   [0165] 
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies   [0165] 
ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo   [0165] 
The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer   [0165] 
Dual immunoregulatory pathways of 4-1BB signaling.   [0165]